Quarterly report · Q2

Period2023-04-01 → 2023-09-30
Filed2023-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
MetricValuePeriodScopeSource row
Revenue¥285.9bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥545.2bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥260.3bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥13.5bn2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥6.4bn2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥14.7bn2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥15.3bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥11.6bn2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥17.5bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥13.1bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥9.9bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.6bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥6.3bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥10.4bn2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥7.1bn2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥1.10Tat 2023-09-30Cons.Assets
Total assets¥1.03Tat 2023-03-31Cons.Assets
Total assets¥1.01Tat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥821.8bnat 2023-09-30Cons.Liabilities
Total liabilities¥785.2bnat 2023-03-31Cons.Liabilities
Net assets / equity¥274.0bnat 2023-09-30Cons.Net assets
Net assets / equity¥242.2bnat 2023-03-31Cons.Net assets
Net assets / equity¥237.2bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥87.2bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥89.7bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥83.8bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥84.7bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥89.9bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥90.1bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥18.7bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥10.4bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥3.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥35.5bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥71.7bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥41.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥8.9bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥43.1bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥23.8bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥60.892023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥35.762023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥28.052022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥38.342022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥5.992022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥53.952023-04-01 → 2023-09-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥24.852022-04-01 → 2023-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥33.972022-04-01 → 2022-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio21.6%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio20.1%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio22.0%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-09-30¥2.5bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-09-30¥417m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-09-30¥2.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-09-30−¥109m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥36.1bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥36.1bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥14.1bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue2023-04-01 → 2023-09-30¥223.6bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue external2023-04-01 → 2023-09-30¥220.2bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥3.3bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentsegment profit2023-04-01 → 2023-09-30¥22.6bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue2023-04-01 → 2023-09-30¥62.9bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue external2023-04-01 → 2023-09-30¥35.2bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥27.6bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentsegment profit2023-04-01 → 2023-09-30¥3.7bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue2023-04-01 → 2023-09-30¥33.0bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue external2023-04-01 → 2023-09-30¥30.0bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥3.1bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentsegment profit2023-04-01 → 2023-09-30¥1.4bn
—segment totalrevenue2023-04-01 → 2023-09-30¥319.5bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥285.4bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥34.0bn
—segment totalsegment profit2023-04-01 → 2023-09-30¥27.7bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥321.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥285.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥36.1bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥27.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-09-30¥2.1bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-09-30¥340m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-09-30¥1.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-09-30¥168m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥18.6bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥18.6bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥15.3bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue2022-04-01 → 2022-09-30¥203.9bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue external2022-04-01 → 2022-09-30¥200.8bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3.1bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentsegment profit2022-04-01 → 2022-09-30¥18.6bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue2022-04-01 → 2022-09-30¥44.9bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue external2022-04-01 → 2022-09-30¥34.1bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥10.8bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentsegment profit2022-04-01 → 2022-09-30¥849m
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue2022-04-01 → 2022-09-30¥28.0bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue external2022-04-01 → 2022-09-30¥25.0bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3.0bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentsegment profit2022-04-01 → 2022-09-30¥2.1bn
—segment totalrevenue2022-04-01 → 2022-09-30¥276.8bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥260.0bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥16.8bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥21.5bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥278.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥260.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥18.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥21.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 644
ItemContextValueUnit
Payroll and allowances sgaCurrentYTDDuration14208000000JPY
Research and development expenses sgaPrior1YTDDuration8445000000JPY
Research and development expenses sgaCurrentYTDDuration7392000000JPY
Provision for bonuses sgaPrior1YTDDuration2907000000JPY
Provision for bonuses sgaCurrentYTDDuration3198000000JPY
Provision for directors bonuses sgaPrior1YTDDuration3000000JPY
Provision for directors bonuses sgaCurrentYTDDuration2000000JPY
Retirement benefit expenses sgaPrior1YTDDuration381000000JPY
Retirement benefit expenses sgaCurrentYTDDuration413000000JPY
Provision for directors retirement benefits sgaPrior1YTDDuration35000000JPY
Provision for directors retirement benefits sgaCurrentYTDDuration36000000JPY
Provision for share based remuneration for directors and other officers sgaPrior1YTDDuration5000000JPY
Provision for share based remuneration for directors and other officers sgaCurrentYTDDuration-JPY
Provision of allowance for doubtful accounts sgaPrior1YTDDuration711000000JPY
Provision of allowance for doubtful accounts sgaCurrentYTDDuration694000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E02688-000MedicalTreatmentRelatedReportableSegmentsMember200823000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E02688-000MedicineRelatedReportableSegmentsMember34133000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E02688-000PharmaPackagingReportableSegmentMember25040000000JPY
Revenues from external customersPrior1YTDDuration_ReportableSegmentsMember259998000000JPY
Revenues from external customersPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember340000000JPY
Revenues from external customersPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember260339000000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember-JPY
Revenues from external customersPrior1YTDDuration260339000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E02688-000MedicalTreatmentRelatedReportableSegmentsMember3080000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E02688-000MedicineRelatedReportableSegmentsMember10798000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E02688-000PharmaPackagingReportableSegmentMember2951000000JPY
Transactions with other segmentsPrior1YTDDuration_ReportableSegmentsMember16829000000JPY
Transactions with other segmentsPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember1751000000JPY
Transactions with other segmentsPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember18581000000JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember-18581000000JPY
Transactions with other segmentsPrior1YTDDuration-JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E02688-000MedicalTreatmentRelatedReportableSegmentsMember203903000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E02688-000MedicineRelatedReportableSegmentsMember44931000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E02688-000PharmaPackagingReportableSegmentMember27992000000JPY
Net salesPrior1YTDDuration_ReportableSegmentsMember276828000000JPY
Net salesPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember2092000000JPY
Net salesPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember278921000000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember-18581000000JPY
Net salesPrior1YTDDuration260339000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E02688-000MedicalTreatmentRelatedReportableSegmentsMember18590000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E02688-000MedicineRelatedReportableSegmentsMember849000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E02688-000PharmaPackagingReportableSegmentMember2096000000JPY
Operating incomePrior1YTDDuration_ReportableSegmentsMember21536000000JPY
Operating incomePrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember168000000JPY
Operating incomePrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember21704000000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember-15332000000JPY
Operating incomePrior1YTDDuration6371000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E02688-000MedicalTreatmentRelatedReportableSegmentsMember220234000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E02688-000MedicineRelatedReportableSegmentsMember35233000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E02688-000PharmaPackagingReportableSegmentMember29980000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass